Design Therapeutics, Inc.DSGNNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank30
3Y CAGR-54.9%
5Y CAGR-68.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-54.9%/yr
Quarterly compound
5Y CAGR
-68.2%/yr
Recent acceleration
Percentile
P30
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 0.47% |
| Q3 2025 | -19.02% |
| Q2 2025 | 15.67% |
| Q1 2025 | 11.11% |
| Q4 2024 | 3.82% |
| Q3 2024 | -3.47% |
| Q2 2024 | -1.57% |
| Q1 2024 | 11.93% |
| Q4 2023 | -26.16% |
| Q3 2023 | 0.60% |
| Q2 2023 | -6.57% |
| Q1 2023 | 15.26% |
| Q4 2022 | 5.09% |
| Q3 2022 | 12.52% |
| Q2 2022 | -5.79% |
| Q1 2022 | 21.66% |
| Q4 2021 | 35.45% |
| Q3 2021 | 5.19% |
| Q2 2021 | 47.37% |
| Q1 2021 | 52.19% |
| Q4 2020 | 142.54% |
| Q3 2020 | 12.93% |
| Q2 2020 | 11.60% |
| Q1 2020 | 0.00% |